Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing
Erin G. Sutcliffe, Amy Stettner, Stacey Miller, Sheila Solomon, Megan L. Marshall, Maegan E. Roberts, Lisa R. Susswein, Kevin J. Arvai, Rachel T. Klein, Patricia D. Murphy, Kathleen S. Hruska
Topics & Concepts
CHEK2Heterozygote advantageMissense mutationProstate cancerCancerGenotypeGeneticsBiologyMedicinePhenotypeOncologyInternal medicineGeneMutationGermline mutationBRCA gene mutations in cancerGenomics and Rare DiseasesGenetic factors in colorectal cancer